Kennedy Cites 147-Participant Hep B Trial at CHD Conference to Question Vaccine Safety Data

Kennedy's address shifted from MAHA food and chemical initiatives to vaccine scrutiny, displaying the Recombivax HB insert and arguing that such limited pre-licensure data would not support FDA approval for other products. Post-licensure studies involving thousands of children and a 99% decline in chronic pediatric hepatitis B infections after universal newborn vaccination were not addressed in the remarks. The administration ended the universal newborn policy last year, prompting ongoing litigation over schedule changes.

The CHD event highlighted Kennedy's emphasis on adverse event reporting gaps and new HHS reviews of over 150 reported events plus Medicare-Medicaid data linkages. Package inserts list temporally associated conditions without established causality, a distinction the speech did not emphasize. Related analyses in Vaccine journal have shown that passive surveillance systems like VAERS require active confirmation studies to assess signals.

Broader context includes rising measles and pertussis cases in under-vaccinated communities following prior policy shifts, consistent with observational data from states with variable exemption rates. Kennedy's framing connects vaccines to chronic disease trends without specifying mechanisms or controlling for diagnostic changes and improved survival.

Next steps include the announced task force on childhood vaccine timing and sequence plus expanded insurer-linked safety monitoring. These efforts will require published protocols and peer-reviewed results to distinguish association from causation.